Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

L. Auclair, Agnès; Martel, J.-C.; Assié, M.B.; Bardin, Laurent; Heusler, Peter; Cussac, Didier; Marien, M.; Newman‐Tancredi, Adrian; O’Connor, J.A.; Depoortère, Ronan

doi:10.1016/j.neuropharm.2013.02.024

Public

Levomilnacipran (F2695), a norepinephrine-preferring SNRI: Profile in vitro and in models of depression and anxiety

Published in Neuropharmacology • Mar 13, 2013

Authors:

Agnès L. Auclair

J.-C. Martel

M.B. Assié

Abstract

Levomilnacipran (LVM; F2695) is the more active enantiomer of the serotonin/norepinephrine (5-HT/NE) reuptake inhibitor (SNRI) milnacipran and is currently under development for the treatment of major depressive disorder. LVM was benchmarked against two other SNRIs, duloxetine and venlafaxine, in bi...

Subject

Milnacipran

Reuptake inhibitor

Duloxetine

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!